NED Biosystems is a clinical-stage company dedicated to developing innovative cancer treatments with the goal of achieving No Evidence of Disease for patients. They have pioneered a systems-based approach to treating complex diseases, starting with their groundbreaking product, NED-170. This patented treatment utilizes repurposed oral agents that have been extensively studied in humans, targeting critical cancer disease-driver processes with minimal toxicity and side effects.

NED-170 is specifically designed to benefit the 50%-80% of cancer patients who do not have genetically sequenced matched therapy options. In response to the global pandemic, NED Biosystems swiftly developed NED-260, a universal antiviral treatment that safeguards cells from a wide range of viruses. The aim of NED-260 is to intervene early in the infection process, reducing the likelihood of severe disease and enabling patients to recover at home.

Their mission is rooted in the belief that safe, effective therapies should be accessible to all, regardless of age, race, economic status, or location. NED Biosystems is committed to reimagining treatments and making a positive impact on two of humanity's most devastating diseases. For more information, please visit their website